

PRECEPTORS AT UNC

Kim L. R. Brouwer, PharmD, PhD

Dr. Brouwer is chair of the Division of Pharmacotherapy and Experimental Therapeutics. Her research, involving both animal and human studies, focuses on: (1) hepatic disposition of xenobiotics and alterations due to disease states, age, patient variables, pharmacologic and/or toxicologic interactions; (2) the development and refinement of *in vitro* model systems to predict *in vivo* hepatobiliary drug disposition and drug interactions; (3) hepatotoxicity; and (4) mechanisms of aberrant drug absorption from the GI tract.

Adam M. Persky, PhD

Dr. Persky joined the UNC faculty in 2004 after completing this fellowship program. His research interests include the disposition and action of dietary supplements and the interaction of exercise and nutrition on drug disposition and action.

Mary Paine, PhD, RPH

Dr. Paine is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. Her research interests include drug metabolism and transport, clinical pharmacokinetics, and drug-xenobiotic interactions. She also directs the UNC Eshelman School of Pharmacy's Cellular Metabolism and Transport Core.

PRECEPTOR AT GSK

Daniele Ouellet, PhD

Dr. Ouellet is a director of clinical pharmacology and simulation at GSK. The company is committed to model-based approaches to enhance the quality and efficiency of drug development. State-of-the-art tools and integrated PK/PD methodologies are applied in the development of compounds within the GSK portfolio to assist in decision-making. Dr. Ouellet has worked in this research area for fourteen years.

For information, contact:

Bob Dupuis, PharmD

Division of Pharmacotherapy and
Experimental Therapeutics
UNC Eshelman School of Pharmacy
3213 Kerr Hall, CB# 7569
Chapel Hill, NC 27599-7569
Email: re_dupuis@unc.edu
Phone: 919-966-6194
Fax: 919-962-0644

Visit the Division of Pharmacotherapy
and Experimental Therapeutics
website to find out more about
our faculty, areas of research,
and programs:
www.pharmacy.unc.edu/dpet



UNC
ESHELMAN
SCHOOL OF PHARMACY

CLINICAL PHARMACOKINETICS & PHARMACODYNAMICS

POSTDOCTORAL FELLOWSHIPS



Sponsored by the

UNC Eshelman
School of Pharmacy
University of North
Carolina at Chapel Hill

in cooperation with

GlaxoSmithKline

A two-year, industry-sponsored
fellowship in clinical pharmacokinetics
and pharmacodynamics

FELLOWSHIP DESCRIPTION

The UNC Eshelman School of Pharmacy, in collaboration with GlaxoSmithKline, sponsors a two-year fellowship in clinical pharmacokinetics/pharmacodynamics for postdoctoral candidates interested in pursuing careers as clinical pharmacologists, clinical pharmacokineticists, or pharmacometricians.

The fellowship provides knowledge and experience in:

- application of pharmacokinetic and pharmacodynamic principles
- clinical pharmacology study design, conduct, analysis and reporting
- drug development
- translational research
- pharmacometric analyses, such as exposure-response and disease-progression models

IDEAL CANDIDATE

Preferred qualifications for the position are a PharmD, PhD, or MD. The ideal candidate should possess strong analytical and programming skills, excellent written and verbal communication, good organizational abilities, and evidence of leadership and team work. A background in pharmacokinetics is preferred. The candidate must be self-directed and self-motivated.

PROGRAM

The goal of the program is to provide research experience that enables the fellow to gain expertise in drug development, quantitative pharmacology, translational research, and/or pharmacometrics while preparing the fellow for a career in this field in an industrial, academic, or regulatory setting.

First Year

Fellows participate in clinical pharmacology, drug transport and metabolism studies with faculty at the UNC Eshelman School of Pharmacy during the first fellowship year. Each fellow will design, initiate, conduct, and analyze various research projects as a part of the learning experience. Fellows enroll in advanced pharmacokinetics/pharmacodynamics and clinical research methods courses, and may attend additional courses, such as biostatistics, advanced therapeutics, drug metabolism, molecular biology, etc.

Second Year

Fellows spend their second year at GlaxoSmithKline as members of a group applying state-of-the-art quantitative methodologies to the development of compounds in the GSK portfolio, such as population pharmacokinetic and pharmacodynamic analyses, exposure-response, disease progression modeling, and clinical trial simulations. Fellows will contribute to the design and analysis of first-time-in-human, proof-of-concept, drug-drug interaction, or other clinical pharmacology studies. Fellows use advanced techniques as they participate in modeling and simulation efforts for quantitative decision making.


APPLICATION PROCESS

The fellowship starts July 1. A competitive stipend, health insurance, and travel to one scientific meeting per year will be offered. Applicants should submit, via e-mail, a letter describing personal goals as related to the fellowship, curriculum vitae, and three professional references by January 1 to:

Bob Dupuis, PharmD
re_dupuis@unc.edu
3213 Kerr Hall, CB #7569
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7569

About UNC and the Triangle

Founded in 1789, the University of North Carolina at Chapel Hill was the first public university established in the United States. Chapel Hill is located approximately two hours from the Atlantic Ocean, and two hours east of the Appalachians. In close proximity to UNC are Duke University, North Carolina State University, and Research Triangle Park, which is home to more than fifty pharmaceutical, biotechnology, health-care, and environmental organizations. Areas for hiking, bicycling, and fishing, as well as theaters, museums, and art galleries are nearby. The sports enthusiast is always at home in Chapel Hill, with a host of collegiate, minor-league, and professional teams nearby.



About GSK

GlaxoSmithKline is one of the largest pharmaceutical companies worldwide. Its mission is to improve the quality of human life by enabling people to do more, feel better, and live longer. GSK produces medicines that treat major disease areas, including asthma, virus control, infections, mental health, diabetes, and digestive conditions. In addition, GSK is a leader in the important area of vaccines and is developing new treatments for cancer. GSK's Research Triangle Park location comprises more than 5,500 employees working in more than forty buildings on more than 100 acres of land.

